2021 Essex County Council election

F+L Week Returns June 14-16, 2023 at the Four Seasons Hotel in Kuala Lumpur, Malaysia

Retrieved on: 
Thursday, December 22, 2022
Automotive, Other Automotive, Oil, Gas, Manufacturing, Energy, Alternative Vehicles, Fuels, Lubricant, Lubrizol, Four Seasons Hotels and Resorts, Annual fuel utilization efficiency, Astral Weeks Live at the Hollywood Bowl, Creativity, 2021 Essex County Council election, Season, Energy, COVID-19, Conference, US, Airline, Renewable energy

Originally known as the Annual Fuels & Lubes Asia Conference, the event celebrates its 28th year in 2023 and will build on the successful return of F+L Week Live!

Key Points: 
  • Originally known as the Annual Fuels & Lubes Asia Conference, the event celebrates its 28th year in 2023 and will build on the successful return of F+L Week Live!
  • The theme for F+L Week 2023 is “Fuels and Lubricants: Navigating the Energy Transition”.
  • “F+L Week 2023 will answer some of the complex questions around the role of fuels and lubricants in a changing energy landscape,” she adds.
  • A dinner at the Four Seasons Hotel, sponsored by Lubrizol, will be held to honour the recipients of the F&L Asia 2023 Awards on June 15.

University Hospitals in Cleveland Enters into Master Purchase Agreement with ViewRay for Multiple MRIdian® Systems

Retrieved on: 
Thursday, January 5, 2023
Cancer, Prostate cancer, Pancreatic cancer, Radiation, Pancreas, Lung, NCI, Research, News, Irritation, Brain, Physics, Breast, Lustgarten Foundation for Pancreatic Cancer Research, Division, Prostate, Surgical oncology, University Hospitals Cleveland Medical Center, Bladder cancer, Nausea, Patient, Radiosurgery, 2021 Essex County Council election, Physician, Hair loss, U.S. News & World Report, Case Western Reserve University School of Medicine, Kidney, Fatigue, Hospital, Kidney cancer, Magnetic resonance imaging, Cryotherapy, Financial toxicity, Radiofrequency ablation, National Cancer Institute, Radiation therapy, Doctor of Philosophy, Liver, Spine, Medical imaging, Urology, Medicine

DENVER, Jan. 5, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the University Hospitals (UH) Seidman Cancer Center in Cleveland has selected a MRIdian MR-Guided Radiation Therapy System as part of a master agreement for the purchase of up to four systems, and will be the first in Ohio at a research and teaching hospital to offer the precision of MRIdian's advanced MRI-guided radiation therapy to cancer patients throughout the region for pancreas, prostate, kidney, gynecological, lung, liver, breast, brain, spine, and oligometastatic cancers.

Key Points: 
  • UH Seidman Cancer Center is part of the NCI-designated Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine.
  • "UH Seidman Cancer Center is at the forefront of clinical excellence and transformative innovation.
  • There was unanimous multi-disciplinary support to bring ViewRay's MRIdian MRI-guided radiotherapy to our center and provide our patients with the latest radiotherapeutic advancements.
  • We aim to continue the advancement of MR-guided adaptive radiotherapy through cutting-edge clinical trials and research to improve patient outcomes.

Calgary is Preparing to Host the World Petroleum Congress to Discuss the Global Energy Transition

Retrieved on: 
Thursday, December 15, 2022
Government of Canada, City, Partnership, UN, WPC, Government, Energy transition, Climate change, European Strategic Programme on Research in Information Technology (ESPRIT), MEG Energy, 2021 Essex County Council election, Parliament, Petrobras, Accreditation, Congress, Union, United Nations, Almas, Accenture, World Petroleum Council, Cenovus Energy, Visa, Suncor Energy, BP, Energy, Calgary Stampede, Government House (Alberta), NGO, BMO Centre, Organization, Strategic planning, Canadian Association of Petroleum Producers, Path, History, Strategy, First Nations in Ontario, Shell Canada, Exhibition, Hatch, Oil, Renewable energy, Pharmaceutical industry

The City of Calgary has also committed to providing important in-kind contributions for the Congress, which will make this world-class event a success.

Key Points: 
  • The City of Calgary has also committed to providing important in-kind contributions for the Congress, which will make this world-class event a success.
  • With sponsorship discussions proceeding with numerous global and Canadian organizations, further sponsorship announcements will be made in the coming weeks.
  • “As a global energy hub, Calgary is taking a leadership role in energy transformation and delivering net zero solutions,” says the Mayor of Calgary, Jyoti Gondek.
  • WPC conducts the triennial World Petroleum Congress, covering all aspects of the industry including management of the industry and its social, economic, and environmental impact.

American Oncology Network Physicians Research Presented at 64th ASH Annual Meeting & Exposition

Retrieved on: 
Wednesday, December 14, 2022
Data set, Physician, 2021 Essex County Council election, Exposition, ASH, AON, ICT, American Society of Pediatric Hematology/Oncology, Research, Society, Bortezomib, Ageing, Pharmaceutical industry, Patient

FORT MYERS, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) is pleased to announce that seven research studies co-authored by AON physicians were presented at the American Society of Hematology (ASH) Annual Meeting & Exposition , held December 10-13 in New Orleans, Louisiana.

Key Points: 
  • FORT MYERS, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) is pleased to announce that seven research studies co-authored by AON physicians were presented at the American Society of Hematology (ASH) Annual Meeting & Exposition , held December 10-13 in New Orleans, Louisiana.
  • The final abstracts featured at the ASH annual meeting represent important, novel research in the field.
  • “With high numbers of submitted materials being considered, the abstracts selected offer premier research findings that are deemed noteworthy and important to cancer care.
  • Launched in 2018, the rapidly expanding AON network represents 107 physicians and 89 nurse practitioners and physician assistants practicing across 18 states.

Florida Cancer Specialists & Research Institute Contributing to Rapid Advancements in Breast Cancer Treatment

Retrieved on: 
Tuesday, December 13, 2022
Breast cancer, Epidermal growth factor, Woman, Immunotherapy, Drug development, U.S. News & World Report, Physician, Stanford University, FACP, VELA, Health, University of Florida Cancer and Genetics Research Complex, 2021 Essex County Council election, Cancer, ASCO, Memorial Sloan Kettering Cancer Center, Fulvestrant, Paclitaxel, Knowledge, News, Recurrence, SERD, CCNE1, MD, FCS, Risk, Monroe Dunaway Anderson, Harvard University, Trastuzumab, American Society of Clinical Oncology, FC Association 1893 Hamburg, Research, Society, RSK, Duke, CDK, Patient, PFS, Medical imaging, Pharmaceutical industry, Birth control

Fort Myers, Florida, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) hematologists and medical oncologists were contributors to several presentations at the San Antonio Breast Cancer Symposium® (SABCS) this past week, sharing the findings of state-of-the-art breast cancer research conducted at FCS.

Key Points: 
  • Fort Myers, Florida, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) hematologists and medical oncologists were contributors to several presentations at the San Antonio Breast Cancer Symposium® (SABCS) this past week, sharing the findings of state-of-the-art breast cancer research conducted at FCS.
  • Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida.
  • Over the past 5 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.
  • Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies, and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy.

HTG Technology Featured Across Numerous Abstracts at Upcoming Scientific Conferences

Retrieved on: 
Tuesday, December 6, 2022
RNA, GEP, Validation, 2021 Essex County Council election, ASH, Roswell Park Comprehensive Cancer Center, HTG, SVP, Research, COVID-19, Non-Hodgkin lymphoma, Diagnosis, Prednisolone, Cancer, Treatment, Rituximab, Society, Precision medicine, Therapy, Drug discovery, Mortality, HTP, First Line, Genmab, BeiGene, CD19, Medicine, Cedars-Sinai Medical Center, Transcriptome, Determinant, Disease, Perelman School of Medicine at the University of Pennsylvania, Lymphocyte, DLBCL, Risk, Pharmaceutical industry, Medical imaging, Medical device, Vincristine, Cyclophosphamide, Patient, Doxorubicin
Key Points: 

    RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium

    Retrieved on: 
    Thursday, December 15, 2022
    Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Symposium, Toxicity, Phase, Cholangiocarcinoma, Pancreatic cancer, Quality of life, Intellectual property, Nature, Security (finance), FDA, 2021 Essex County Council election, Safety, ASCO, Treatment, Pressure, Drug Quality and Security Act, Gastrointestinal cancer, MD, Efficacy, Research, Radiosurgery, COVID-19, Patient, Pharmaceutical industry, Medical imaging, EU, LAPC

    RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced the acceptance of four clinical data abstracts supporting its lead oncology product candidate, RenovoGem, and its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform to be presented at the 2023 ASCO Gastrointestinal Cancers Symposium (ASCO GI).

    Key Points: 
    • RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced the acceptance of four clinical data abstracts supporting its lead oncology product candidate, RenovoGem, and its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform to be presented at the 2023 ASCO Gastrointestinal Cancers Symposium (ASCO GI).
    • The Symposium is to be held on January 19-21, 2023 in San Francisco, California and online.
    • "These research presentations will mark the beginning of a significant year at RenovoRx, said Shaun Bagai, CEO of RenovoRx.
    • We also plan to launch a clinical program in extrahepatic Cholangiocarcinoma (bile duct cancer), the second clinical indication for RenovoGem and the RenovoTAMP platform.

    MMRF Programs Drive Advances in Cancer Research at 64th American Society of Hematology (ASH) Annual Meeting

    Retrieved on: 
    Monday, December 12, 2022
    Other Health, Research, General Health, Pharmaceutical, Philanthropy, Oncology, Foundation, Clinical Trials, Science, Biotechnology, Other Science, Health, Melanoma, Multiple Myeloma Research Foundation, Multiple myeloma, Daratumumab, Arm, Immune system, MMRF, ORR, IPD, Immunotherapy, Diagnosis, CD38, Society, Biomarker, Patient, 2021 Essex County Council election, Cancer, MAPK, Research, Precision medicine, Neoplasm, FDA, Risk assessment, MMRC, Dexamethasone, Genomics, Bone marrow, Clinical trial, Tissue, ASH, Pharmaceutical industry, Vaccine

    The insights gained by these two innovative studies demonstrate the importance of generating and sharing a wide array of data.

    Key Points: 
    • The insights gained by these two innovative studies demonstrate the importance of generating and sharing a wide array of data.
    • The MMRC focuses primarily on trials like MyDRUG that require the collaboration of many sites, given their specificity and scale.
    • The MMRF CoMMpass Study is an ongoing longitudinal study of patients with newly diagnosed active multiple myeloma.
    • The MMRF has raised more than $500 million and directs nearly 90% of the total funds to research and related programs.

    Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session

    Retrieved on: 
    Sunday, December 11, 2022
    Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Congress, Security (finance), Therapy, Pancreatic serous cystadenoma, BET, Society, Research, 2021 Essex County Council election, Patient, Prevalence, ET, MF, Polycythemia, Ruxolitinib, Disease, FDA, GVHD, COVID-19, Cell, Lymphatic system, Human, JAK2, Bone marrow, Annual report, Safety, University, ALK2, CALR, Doctor of Philosophy, Marketing, ASH, Abstract, Mutation, Graft-versus-host disease, Pharmaceutical industry, Vaccine, Wood drying, Calreticulin, Myeloproliferative neoplasm, Incyte

    This research was featured in the Plenary Scientific Session (Abstract #6.

    Key Points: 
    • This research was featured in the Plenary Scientific Session (Abstract #6.
    • Session: Hematology Disease Topics & Pathways: Research, Diseases, Therapies, Myeloid Malignancies) at the 64th American Society of Hematology (ASH) Annual Meeting, held December 10-13, 2022, in New Orleans and virtually1.
    • CALR mutations are responsible for disease development in approximately 25-35%2,3 of patients with MF and ET two common types of MPNs.
    • INCA033989 binds with high affinity to mutant CALR and inhibits oncogenesis, the process of cells becoming cancerous, in cells expressing this oncoprotein.

    The Modern Data Company Launches DataOS®

    Retrieved on: 
    Wednesday, December 7, 2022
    Software, Networks, Internet, Data Management, Technology, Apps, Applications, Mobile, Wireless, Other Technology, ANY, Trust, Intelligence, Platform as a service, 2021 Essex County Council election, Data management, IOT, Freedom, Video game console, Medical device

    The Modern Data Company today announced DataOS, the world's first multi-cloud data operating system that makes data simple for enterprises to drive decisions.

    Key Points: 
    • The Modern Data Company today announced DataOS, the world's first multi-cloud data operating system that makes data simple for enterprises to drive decisions.
    • Created to quickly operationalize complex data infrastructures, DataOS is a modern, open and composable data management platform as a service (PaaS) that provides total data visibility and turns data into insights that drive actionable intelligence.
    • DataOS makes your existing legacy infrastructure work like a modern data stack without rip-and-replacing anything, said Srujan Akula, CEO and co-founder of The Modern Data Company.
    • The Modern Data Company is redefining data management with DataOS; the worlds first multi-cloud, programmable data operating system.